Trials / Completed
CompletedNCT06573606
Ophthalmic Solution in Diabetic Corneal Alteration
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 20 (actual)
- Sponsor
- D&V FARMA srl · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Data analyses and revision of the DED symptoms in diabetic subjects. A novel ophthalmic solution containing cross-linked ha (CX-HA) and Chondroitin sulphate (CS) has been made available on the market. Both molecules have been widely studied for their viscoelastic and hydrating properties. Nevertheless, the use of CS in ophthalmology has been limited since, routinely, the molecule is of animal origins. This new ophthalmic solution is the first on the market formulated with a CS of non-animal origin.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | CX-HA and CS | Sterile Isotonic ophthalmic solution |
Timeline
- Start date
- 2021-09-01
- Primary completion
- 2022-09-01
- Completion
- 2022-09-01
- First posted
- 2024-08-27
- Last updated
- 2024-08-29
Locations
1 site across 1 country: Italy
Source: ClinicalTrials.gov record NCT06573606. Inclusion in this directory is not an endorsement.